FY2024 Earnings Forecast for ALNY Issued By Zacks Research

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Investment analysts at Zacks Research lifted their FY2024 EPS estimates for Alnylam Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 14th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of ($2.50) for the year, up from their prior forecast of ($2.52). The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals' Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($3.16) EPS, Q1 2026 earnings at $0.34 EPS, Q2 2026 earnings at $0.11 EPS and FY2026 earnings at $1.74 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business's quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 EPS.

A number of other research firms also recently weighed in on ALNY. HC Wainwright restated a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday. Wolfe Research cut shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Sanford C. Bernstein cut their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $298.61.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $2.89 during mid-day trading on Friday, hitting $246.27. 556,461 shares of the stock were exchanged, compared to its average volume of 679,404. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The stock has a market capitalization of $31.76 billion, a price-to-earnings ratio of -94.00 and a beta of 0.34. The business has a fifty day moving average price of $246.62 and a 200 day moving average price of $259.70. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the transaction, the chief marketing officer now directly owns 15,705 shares of the company's stock, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,122 shares of company stock worth $2,540,455. Company insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $29,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $42,000. True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $45,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.